hoʻokolohua lapaʻau maʻi maʻi prostate

Nā lāʻau lapaʻau maʻi prostate hoʻokolohua hāʻawi i ka manaʻolana no nā maʻi i ka wā ʻaʻole maikaʻi nā lāʻau lapaʻau maʻamau. Loaʻa pinepine kēia mau lāʻau lapaʻau ma o nā hoʻokolohua lapaʻau, e noiʻi ana i nā ala hou e like me ka immunotherapy, nā mea lapaʻau i hoʻopaʻa ʻia, ka lāʻau lapaʻau, a me nā ʻenehana radiation holomua. ʻOiai e hoʻokolokolo ʻia ana, hiki i kēia mau koho ke hāʻawi i nā pono nui no kekahi poʻe. ʻOiai e kūleʻa pinepine ana nā lāʻau kuʻuna e like me ka hōʻoki ʻana, radiation therapy, a me ka hormone therapy, ke kū nei kekahi mau hihia, pono ke ʻimi hoʻokolohua lapaʻau maʻi maʻi prostate.Standard Prostate Cancer TreatmentsMa mua o ka noonoo ana hoʻokolohua lapaʻau maʻi maʻi prostate, he mea nui e hoʻomaopopo i nā koho maʻamau. ʻO kēia mau mea kēia: ʻO ka ʻokiʻoki (Prostatectomy) ʻO ka Radiation Therapy (External Beam, Brachytherapy) Hormone Therapy (Androgen Deprivation Therapy) ChemotherapyWhen e noʻonoʻo ai i nā lapaʻau hoʻokolohua.Nā lāʻau lapaʻau maʻi prostate hoʻokolohua noʻonoʻo pinepine ʻia ke hāʻule ʻole a ʻaʻole pono nā lāʻau maʻamau. Hiki i nā maʻi me ka maʻi maʻi prostate kiʻekiʻe a i ʻole metastatic ke ʻimi i kēia mau koho. He mea nui e kūkākūkā me kāu kauka oncologist inā he komo ʻana i kahi hoʻokolohua lapaʻau a i ʻole e ʻimi ana i kahi hoʻokolohua lapaʻau maʻi maʻi prostate kūpono iā ʻoe. Nā ʻano o nā lāʻau lapaʻau maʻi maʻi prostate hoʻokolohua hoʻokolohua lapaʻau maʻi maʻi prostate ke hoʻokolokolo ʻia nei i kēia manawa. ʻO kēia mau mea: ImmunotherapyImmunotherapy hoʻohana i ka mana o ka ʻōnaehana pale o ke kino e hakakā ai i nā maʻi maʻi maʻi. ʻO nā laʻana o ka maʻi prostate penei:ʻO nā mea hoʻopaʻapaʻa hōʻoia: Hiki i nā lāʻau lapaʻau e like me ka pembrolizumab a me ka nivolumab ke pale i nā protein e pale ai i ka ʻōnaehana pale mai ka hoʻouka ʻana i nā maʻi kanesa.Kaʻa T-Cell Therapy: ʻOiai e hoʻomaka ana ka hoʻomohala ʻana no ka maʻi maʻi prostate, ʻo ka CAR T-cell therapy e pili ana i ka hoʻololi ʻana i nā cell T o ka mea maʻi e hoʻopaʻa ʻia a luku i nā maʻi maʻi.Nā lāʻau lapaʻau maʻi maʻi maʻi: Hoʻoulu kēia mau lāʻau lapaʻau i ka ʻōnaehana pale e ʻike a hoʻouka i nā maʻi maʻi prostate. ʻO Provenge (sipuleucel-T) he lāʻau lapaʻau i ʻāpono ʻia, a ke kūkulu nei nā mea noiʻi i nā hoʻolālā kano hou. Nā mea pale PARP: ʻO nā lāʻau lapaʻau e like me ka olaparib a me ka rucaparib e kuhikuhi ana i nā enzymes PARP, i komo i ka hoʻoponopono DNA. He kūpono lākou i nā maʻi maʻi prostate me kekahi mau hoʻololi genetic (e laʻa, BRCA1/2).Nā mea pale PI3K/AKT/mTOR: Kuhi ʻia kēia mau lāʻau i nā ala hōʻailona e hāpai i ka ulu ʻana o ka maʻi kanesa. Ke noiʻi ʻia nei lākou i nā hoʻokolohua lapaʻau no ka maʻi maʻi prostate.Radiopharmaceuticals: Hāʻawi kēia mau lāʻau lapaʻau i ka radiation i nā maʻi kanesa. ʻO Lutetium-177 PSMA-617 kahi radiopharmaceutical i ʻāpono ʻia e hoʻopaʻa ana i ka PSMA (prostate-specific membrane antigen), he protein i loaʻa ma nā maʻi maʻi prostate. Ke ʻimi nei ka poʻe noiʻi i nā ʻano lāʻau lapaʻau e hoʻopuka pololei i nā genes hakakā i ka maʻi maʻi maʻi prostate a i ʻole e hoʻonui i ka hiki o ka ʻōnaehana pale ke ʻike a hoʻouka i ka maʻi kanesa.ʻO ka hoʻomaʻamaʻa ʻana o ke kino stereootactic (SBRT): Hāʻawi i nā kiʻekiʻe kiʻekiʻe o ka radiation i kahi wahi liʻiliʻi i kuhikuhi pono ʻia.Lapaʻau Proton: Hoʻohana i nā protons ma kahi o nā kukui X, hiki ke hōʻemi i ka pōʻino i nā ʻiʻo a puni. hoʻokolohua lapaʻau maʻi maʻi prostate. ʻO ke komo ʻana i kahi hoʻokolohua lapaʻau hiki ke hāʻawi i ke komo i nā lāʻau lapaʻau ʻokiʻoki a kōkua i ka holomua ʻana i ka noiʻi maʻi kanesa. He mea nui e noʻonoʻo i nā koina hoʻokomo / hoʻokuʻu ʻia, nā hopena ʻaoʻao kūpono a me ka hoʻolālā haʻawina holoʻokoʻa. Manaʻo ʻia e ʻimi i ka ʻōlelo aʻoaʻo mai kāu hui mālama lapaʻau ma mua o ka noʻonoʻo ʻana i ke kākau inoa ʻana i kekahi hoʻokolohua lapaʻau.Huli Ho'āʻo Hoʻāʻo Hoʻomaʻamaʻa National Cancer Institute (NCI).ClinicalTrials.govNā Manaʻo Nui Ma mua o ka hahai ʻana hoʻokolohua lapaʻau maʻi maʻi prostate, e noʻonoʻo i kēia: Kūkākūkā me kāu Oncologist Kūkākūkā i nā koho lapaʻau a pau me kāu oncologist, me nā pono kūpono a me nā pilikia o hoʻokolohua lapaʻau maʻi maʻi prostate.Ka hoomaopopo ana i na pilikia a me na pomaikai E kaupaona pono i na pono o ka hoʻokolohua lapaʻau maʻi maʻi prostate kū'ē i nā pilikia a me nā hopena ʻaoʻao. Loaʻa paha nā hopena ʻaoʻao i ʻike ʻole ʻia a hiki ʻole paha i nā lāʻau hoʻokolohua. Uku a me ka uhi ʻinikua e nānā me kāu mea hoʻolako inikua e hoʻoholo ai i ka uhi no hoʻokolohua lapaʻau maʻi maʻi prostate. Hiki ke ʻokoʻa nā kumukūʻai, a ʻaʻole hiki ke uhi ʻia kekahi mau lapaʻau. Hope no ka wā e hiki mai anaNā lāʻau lapaʻau maʻi prostate hoʻokolohua hāʻawi i ka manaʻolana no nā maʻi i pau nā koho lapaʻau maʻamau. Ma o ka hoʻomau ʻana i ka noiʻi a me nā hoʻokolohua lapaʻau, ke kūkulu nei nā ʻepekema i nā ala hou a me nā ala hou e hakakā ai i kēia maʻi. Shandong Baofa Cancer Research Institute ua hoʻolaʻa ʻia no ka ʻimi ʻana i nā lāʻau lapaʻau maʻi maʻi holomua. Ma ke ʻano he kumu alakaʻi i ka noiʻi maʻi maʻi, ua kūpaʻa mākou i ka hoʻomaikaʻi ʻana i ke ola o nā maʻi ma o ka hoʻomohala ʻana i nā hoʻolālā therapeutic novel. ʻO ka hoʻomaopopo ʻana i ka PSMA-Targeted TherapyPSMA, a i ʻole prostate-specific membrane antigen, he pūmua i loaʻa i nā pae kiʻekiʻe ma ka ʻili o nā sela maʻi prostate. Hoʻolilo kēia i mea waiwai nui no hoʻokolohua lapaʻau maʻi maʻi prostate.How PSMA-Targeted Therapy Works Ua hoʻolālā ʻia nā lāʻau lapaʻau i hoʻopaʻa ʻia e PSMA e hoʻopaʻa pono iā PSMA ma nā pūnaewele maʻi prostate, e hāʻawi pololei ana i ka uku therapeutic i ka ʻōpū. Ke manaʻo nei kēia ala e hōʻemi i ka pōʻino i nā cell olakino. Nā Laʻana o PSMA-Targeted Therapies Lutetium-177 PSMA-617: Hoʻohui kēia radiopharmaceutical i kahi molekole PSMA-targeting me ka radioactive isotope lutetium-177. Hāʻawi ia i ka radiation i manaʻo ʻia i ka PSMA-expressing prostate cancer cells. E ʻike i ka ʻikepili ma aneʻi: FDA.gov ʻO ka Immunotherapy i koho ʻia e PSMA: Ke hoʻomohala nei nā mea noiʻi i nā immunotherapies e kuhikuhi ana iā PSMA e hoʻoulu i ka ʻōnaehana pale e hoʻouka i nā pūnaewele maʻi prostate. The Role of Genetic Testing in Experimental Treatment Decisions hoʻokolohua lapaʻau maʻi maʻi prostate. Hiki i kekahi mau hoʻololi genetic ke wānana i ka maikaʻi o ka pane ʻana o ka mea maʻi i nā lāʻau lapaʻau kūikawā, ʻoi aku ka nui o nā lāʻau lapaʻau e like me PARP inhibitors. Common Genetic Mutations in Prostate Cancer. BRCA1 a me BRCA2: Hoʻopili kēia mau genes i ka hoʻoponopono DNA. Hiki i ka hoʻololi ʻana i kēia mau genes ke hoʻololi i nā maʻi maʻi maʻi i ka PARP inhibitors. ATM: ʻO kekahi gene i pili i ka hoʻoponopono DNA. Hiki i ka hoʻololi ʻana i ka ATM ke hoʻonui i ka naʻau i nā mea paʻa PARP. MSH2, MSH6, MLH1, PMS2: Hoʻopili kēia mau genes i ka hoʻoponopono mismatch. Hiki i ka hoʻololi ʻana i kēia mau genes ke alakaʻi i ka microsatellite instability (MSI), ka mea e maʻalahi ai nā sela maʻi kanesa i ka immunotherapy. Therapies PARP Inhibitors, PI3K/AKT/mTOR Inhibitors, Radiopharmaceuticals Hoʻokomo i nā genes i loko o nā pūnaewele e mālama i ka maʻi Hiki no ke kala ʻana o ka maʻi maʻi maʻi ʻoi aku ka pololei, hiki ke emi i nā hopena ʻaoʻao i hoʻohālikelike ʻia me ka lāʻau lapaʻau kuʻuna Gene Therapy Hoʻokomo i nā genes i loko o nā cell e mālama ai i ka maʻi Hiki no ke kala lōʻihi, hoʻopaʻa ʻia ʻo Radirapton. ʻoi aku ka pololei, e hōʻemi ana i ka pōʻino i nā ʻiʻo olakino He liʻiliʻi nā hopena ʻaoʻao i hoʻohālikelike ʻia me ka lāʻau lapaʻau kuʻuna, hiki ke hāʻawi ʻia i nā pona kiʻekiʻe.